Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.
René-Jean Bensadoun,Phillipe Humbert,Jean Krutman,Thomas A. Luger,Raoul Triller,André Rougier,Sophie Seité,Brigitte Dréno +7 more
TLDR
The present guidelines were developed by a board of European experts in dermatology and oncology to provide cancer care professionals with guidance for the appropriate use of non-pharmaceutical, dermocosmetic skin care management of cutaneous toxicities associated with radiotherapy and systemic chemotherapy, including epidermal growth factor inhibitors and monoclonal antibodies.Abstract:
Skin reactions due to radiotherapy and chemotherapy are a significant problem for an important number of cancer patients. While effective for treating cancer, they disturb cutaneous barrier function, causing a reaction soon after initiation of treatment that impacts patient quality of life. Managing these symptoms with cosmetics and nonpharmaceutical skin care products for camouflage or personal hygiene may be important for increasing patient self-esteem. However, inappropriate product choice or use could worsen side effects. Although recommendations exist for the pharmaceutical treatment of skin reactions, there are no recommendations for the choice or use of dermatologic skin care products for oncology patients. The present guidelines were developed by a board of European experts in dermatology and oncology to provide cancer care professionals with guidance for the appropriate use of non-pharmaceutical, dermocosmetic skin care management of cutaneous toxicities associated with radiotherapy and systemic chemotherapy, including epidermal growth factor inhibitors and monoclonal antibodies. The experts hope that these recommendations will improve the management of cutaneous side effects and hence quality of life for oncology patients.read more
Citations
More filters
Journal ArticleDOI
Microbiome in healthy skin, update for dermatologists
Brigitte Dréno,Elena Araviiskaia,Enzo Berardesca,G. Gontijo,M. Sanchez Viera,Leihong Flora Xiang,Richard Martin,T. Bieber +7 more
TL;DR: An overview on the knowledge about the skin microbiota, the microbiome and their importance in dermatology is provided to understand how microbial diversity may contribute to skin health and dermatological conditions.
Journal ArticleDOI
Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review.
Elaine Barros Ferreira,Christiane Inocêncio Vasques,Rafael Gadia,Raymond Javan Chan,Eliete Neves Silva Guerra,Luis André Mezzomo,Graziela De Luca Canto,Paula Elaine Diniz dos Reis +7 more
TL;DR: Wang et al. as discussed by the authors evaluated the effects of pharmacological and non-pharmacological topical controls in the prevention of radiation dermatitis in patients undergoing head and neck cancer undergoing radiotherapy.
Journal ArticleDOI
Interplay Between the Host, the Human Microbiome, and Drug Metabolism.
TL;DR: The microbiome may be important to consider during drug discovery, risk assessment, and dosing regimens for various diseases given that the human microbiome has been shown to impact host detoxification processes.
Journal ArticleDOI
Prevention and treatment of acute and chronic radiodermatitis
TL;DR: The objective of this paper is to review how to prevent or manage the symptoms of radiodermatitis reactions and suggests that LLLT has biostimulating properties which allow the tissues to regenerate and heal faster, reduce inflammation, and prevent fibrosis.
Journal ArticleDOI
Radiotherapy-induced skin reactions: assessment and management
Deborah Glover,Victoria Harmer +1 more
TL;DR: The aims and nature of radiotherapy are outlined, the aetiology of skin reactions, risk factors for reaction, and assessment tools are discussed, and management interventions will be shown, with emphasis on silicone dressings.
References
More filters
Journal ArticleDOI
Mechanisms of cutaneous toxicities to EGFR inhibitors.
TL;DR: There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy.
Journal ArticleDOI
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Siegfried Segaert,E. Van Cutsem +1 more
TL;DR: The broad spectrum of cutaneous side-effects of EGFR inhibitors is outlined, possible underlying mechanisms are discussed and practical guidelines for the management are provided based on literature data and on personal experience.
Journal ArticleDOI
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Caroline Robert,Jean-Charles Soria,Alain Spatz,Axel Le Cesne,David Malka,Patricia Pautier,Janine Wechsler,Catherine Lhommé,Bernard Escudier,Valérie Boige,Jean-Pierre Armand,Thierry Le Chevalier +11 more
TL;DR: The cutaneous side-effects seen after treatment with the inhibitors of epidermal-growth-factor receptor (EGFR), imatinib, sorafenib, and sunitinib are discussed, which could lead to the identification of crucial predictive factors for tumour response.
Journal ArticleDOI
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
TL;DR: Findings suggest that there is a relationship between the development of rash and response and/or survival, making rash a potential surrogate marker of activity.
Journal ArticleDOI
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
TL;DR: Physicians and patients should view rash development as a positive event indicative of greater likelihood of clinical benefit and further studies are required to identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.